Miguel F. Segura

Universitat Autònoma de Barcelona — Spain

Biochemistry, Genetics and Molecular Biology · Life Sciences

35h-index5.1kcitations150works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

MicroRNA in disease regulation(31), Neuroblastoma Research and Treatments(28), Protein Degradation and Inhibitors(25), Cell death mechanisms and regulation(17), Cancer-related molecular mechanisms research(17)

Publications150 total

Plasmid DNA Delivery Using a Stable Nanovesicle Platform: A Design-of-Experiments-Guided Investigation
ACS Biomaterials Science & Engineering·2025Open Access
Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches
Epigenomics·2025· 1 citedOpen Access
Complete Remission With Fourth-Line Immunotherapy After Chemotherapy Failure in a Lung Cancer Patient With Severe Autoimmune Disease: An Unexpected Turn in Oncologic Management
Cureus·2025Open Access
26P Cervical cancer in trans people: Equity gap and challenges for health policies
ESMO Open·2025Open Access
Safety and tolerability of a bevacizumab biosimilar (Effivia®) in adult Mexican patients with cancer: a multicenter, observational, prospective clinical study
Frontiers in Drug Discovery·2025Open Access
BORA overexpression promotes epithelial–mesenchymal transition and metastasis in ovarian cancer: Unveiling a novel therapeutic target for advanced disease
Clinical and Translational Medicine·2025· 3 citedOpen Access
Combined inhibition of MDM2 and PARP lead to a synergistic anti-tumoral response in p53 wild-type rhabdomyosarcoma models
2024Open Access
21521. CARACTERIZACIÓN CLÍNICA DE 64 PACIENTES CON ANTICUERPOS CONTRA LA PROTEÍNA ÁCIDA FIBRILAR GLIAL (GFAP)
Neurology Perspectives·2024Open Access
Study of the Relationship Between the Area of the Rectus Femoris Measured by Ultrasound and Psoas Muscle Index (PMI) and Skeletal Muscle Index (SMI) Measured by Opportunistic CT in Oncological Surgical Patients
Preprints.org·2024· 1 citedOpen Access
Advances in the approaches used to repurpose drugs for neuroblastoma
Expert Opinion on Drug Discovery·2024· 3 cited
In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma
PLoS ONE·2024· 2 citedOpen Access
TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma
Experimental Hematology and Oncology·2024· 9 citedOpen Access
Clusterin deficiency is associated with a lack of response to teriflunomide in multiple sclerosis
Clinical and Translational Medicine·2024· 2 citedOpen Access
Abstract 5473: Combined inhibition of MDM2 and PARP lead to a synergistic anti-tumoral response in p53 wild-type rhabdomyosarcoma
Cancer Research·2024
TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma
2023Open Access
Maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients
Translational Pediatrics·2023· 6 citedOpen Access
Supplementary Data from Melanoma MicroRNA Signature Predicts Post-Recurrence Survival
2023Open Access
Supplementary Data from Melanoma MicroRNA Signature Predicts Post-Recurrence Survival
2023Open Access
Data from Melanoma MicroRNA Signature Predicts Post-Recurrence Survival
2023Open Access
Data from Melanoma MicroRNA Signature Predicts Post-Recurrence Survival
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Eva Hernando(16), Aroa Soriano(14), Joan X. Comella(13), Soledad Gallego(12), Iman Osman(11), Josep Roma(9), Douglas Hanniford(8), Farbod Darvishian(7), Luz Jubierre(7), Joan Sánchez-de-Toledo(7), Rana S. Moubarak(6), Carla Molist(6), Sílvia Menéndez(5), Jiří Zavadil(5), Anna C. Pavlick(5), Laura Planells‐Ferrer(5), Ana Almazán-Moga(5), Carme Solé(5), Laia París-Coderch(4), Marc Masanas(4)